|
|
Michael Snyder: You can almost always count on the Supreme Court to do the wrong thing. In fact, just about every major decision by the U.S. Supreme Court Read more…
Michael Johnston: After a slew of announcements early Monday prompted speculation that a decision on health care legislation was imminent, we learned that Thursday will be the day for one of the most heavily anticipated rulings in the last several years. Read more…
While a number of companies are on the verge of hitting the market with exciting new drug products or medical treatments, the biggest 2011 profits for investors in the biotech stocks are Read more…
David Fry From ETF Digest goes into detail on two biotech ETFs discussing the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) and the ProShares Ultra Nasdaq Biotechnology ETF Read more…
March was the 10th anniversary of the beginning of the “tech wreck” when the NASDAQ peaked at 5132 on March 10, 2000. As we look back ten years and all that has transpired in technology and Read more…
“It is our opinion, along with that of many other market professionals, that this current market is overbought. An overbought market often searches for a place, or more to the point, a reason to pull Read more…
“Last week a number of biotech players, including Millipore (MIL), OSI Pharmaceuticals (OSIP), Intermune (ITMN) and Sequenom (SQNM) turned in double-digit gains in the volatile health care Read more…
Investors looking to boost their portfolios with health care exposure while limiting the risks of company-specific occurrences might want to give their portfolios the basket treatment Read more…
Most Comments